An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Vaso-occlusive Crises
Latest Information Update: 19 Apr 2024
At a glance
- Drugs Crizanlizumab (Primary)
- Indications Vaso-occlusive crisis
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 05 Mar 2024 Status changed from active, no longer recruiting to completed.
- 30 Jan 2024 Planned End Date changed from 15 Feb 2024 to 13 Feb 2024.
- 30 Jan 2024 Planned primary completion date changed from 14 Feb 2024 to 13 Feb 2024.